33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss

The document presents an analysis of two randomized, double-blinded, placebo-controlled trials (BRAVE-AA1 and BRAVE-AA2) evaluating the efficacy of Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, in promoting eyebrow and eyelash regrowth in patients with severe alopecia areata (AA) who did not achieve a Severity of Alopecia Tool (SALT) score ≤20 (20% or less scalp hair loss) at Week 36. The results showed that in patients with a SALT score >20 at Week 36, treatment with baricitinib 4 mg resulted in achievement rates of 19.8% for ClinRo EB (0, 1) and 22.6% for ClinRo EL (0, 1) versus 3.5-3.9% with placebo (P ≤ .001). For baricitinib 2 mg, the rate of ClinRo EB (0, 1) was 10.4% (P ≤ .01 versus placebo 3.5%) and ClinRo EL was 9.4% (P = .051, versus placebo 3.9%). Therefore, baricitinib therapy resulted in clinically meaningful improvement in hair growth for eyebrows and eyelashes in those with SALT score >20 at Week 36.